Study S002421

Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07708610
Study type: OBSERVATIONAL
Status: NOT_YET_RECRUITING
Enrollment: 71775
Start: 2026-07-31
Primary completion: 2026-08-31
Lead sponsor: Chung Shan Medical University
Conditions: Pneumonia; Type 2 Diabetes Mellitus (T2DM)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Composite outcome (all-cause mortality, invasive mechanical ventilation, or renal replacement therapy) [Within 30 days after the index pneumonia admission]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006102	Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. Simms-Williams N, BMJ (Clinical research ed.)	2024	Nonrandomized study	PMID 38663919 DOI	registry reference BACKGROUND:38663919
R0006899	Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Wright AK, Diabetes care	2022	Systematic review	PMID 35100355 DOI	registry reference BACKGROUND:35100355